TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh
Brief Summary: The purpose of this community-based randomized trial is to examine whether a daily antenatal and postnatal multiple micronutrient supplement given to women will enhance newborn and infant survival and health and other birth outcomes in a rural setting in northwestern Bangladesh.


Options:
A: Inclusion Criteria:

All the women of child-bearing age (15-44 years) living in the study area (4 100) will be visited monthly to assess early pregnancy and will be invited to participate in the trial.

Exclusion Criteria:

Will be excluded from the study women :

* planning to move outside the district within the 2 years following the start of the trial.
* regularly using a contraceptive method.
* already pregnant at the start of the trial.
B: Inclusion Criteria:

* 18-35 years old
* Currently married
* Currently living in one of the 10 communes and intends to live in the areas for 24 months following recruitment
* Plans to have children in the next year
* Agrees to participate with informed consent

Exclusion Criteria:

* Currently pregnant
* Delivered in the previous six months
* Regularly consumed IFA or MM supplements in the past 2 months
* Severe anemia (Hb \< 7 g/L)
* History of high risk pregnancy including abruptio placenta, placenta previa, gestational diabetes, pregnancy induced hypertension, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use
* Chronic hematological diseases, hereditary defects of red cells or hemoglobin
C: Inclusion Criteria:

* Pregnant and consents to participate

Exclusion Criteria:

* Not interviewed for consent within 12 consecutive weeks after being ascertained as pregnant by urine testing
D: Inclusion Criteria:

* Women with cleft lip with/out palate (CLP), 16 to 45 years of age registered at the study clinics in Brazil or Women (16 to 45 years of age) with at least one natural child of any age with CLP registered at the study clinics.
* Women must reside in the catchment area of the study, which includes the states where the study clinics are located and surrounding states.

Exclusion Criteria:

* Consanguineous couples (up to third degree, i.e. first cousins or closer).
* Pregnany at the time of recruitment. Women will be recontacted later at an appropriate time for participation in the study.
* Couples either one of which have been sterilized.
* Taking any form of seizure medication.
* Planning to move outside of the study catchment area within the next year.
* B12 deficiency (\<174 pg/mL or 129.15 pmol/L).
* Being allergic to folic acid.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh
Brief Summary: The purpose of this community-based randomized trial is to examine whether a daily antenatal and postnatal multiple micronutrient supplement given to women will enhance newborn and infant survival and health and other birth outcomes in a rural setting in northwestern Bangladesh.


Options:
A: Inclusion Criteria:

* Pregnant and consents to participate

Exclusion Criteria:

* Not interviewed for consent within 12 consecutive weeks after being ascertained as pregnant by urine testing
B: Inclusion Criteria:

* Currently exposed to arsenic via contaminated drinking water
* Well water arsenic concentration \> 10 ug/L
* Between the ages of 20 and 65

Exclusion Criteria:

* Women who are currently pregnant or plan to become pregnant within the next 6 months
* Currently taking nutritional supplements
* Known renal disease
* Participation in any other clinical trial
C: Inclusion Criteria:

* Men or women more than 18 years of age and chronically exposed to arsenic (arsenic concentration of the drinking water \>10ug/L);
* Population who had no folic acid supplementation in the 2 weeks before the study;
* Women of childbearing age agreed to use a reliable contraception method during the study;
* Everyone volunteered to participate and signed informed consent.

Exclusion Criteria:

* Pregnant or breast-feeding women;
* Allergic to folic acid;
* Having clearly defined allergic history;
* Reported long-term use of folic acid and other vitamins B;
* Having obvious signs or laboratory abnormalities which could affect the efficacy of folic acid;
* Unsuitable to participate in the study based on the judgment of the investigators;
* Not agree to cancel the medications which may affect serum folate concentration during the study period;
* Subjects who plan to become pregnant during the study or move out of the area within the study period;
D: Inclusion Criteria:

* Age-eligible children of parents enrolled in the Health Effects of Arsenic Longitudinal Study cohort

Exclusion Criteria:

* siblings
* twins
* children who are not attending school
* children with known physical disability or known chronic illness

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Case Volume and Adenoma Detection Rates During Screening Colonoscopy
Brief Summary: Screening colonoscopy has been established as the most effective means of colorectal cancer prevention. This is based on the fact that colonoscopy detects and removes colonic polyps (adenomas) which are known to progress to cancer if left untreated. The present study examines the question whether case volume (i.e., the number of colonoscopies performed per year) correlates with colonoscopy quality, i.e., adenoma detection rate.


Options:
A: Inclusion Criteria:

* Asymptomatic persons \> 55 years willing to undergo screening colonoscopy

Exclusion Criteria:

* Missing consent
* Symptomatic persons
* Poor general conditions, significant comorbidity
B: Inclusion Criteria:

* At least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment.
* Both Helicobacter pylori positive and negative patients eligible (Helicobacter pylori is a bacterial infection of the stomach)

Exclusion Criteria:

* Presence of clinical significant abnormal findings at the endoscopy (examination of esophagus and stomach) prior to enrollment.
* Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD).
* Helicobacter pylori eradication treatment during the last 12 months prior to enrollment.
C: Inclusion Criteria:

* Subject between the ages of 18 and 70
* The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic workup;
* Written informed consent must be available before enrollment in the trial
* For women with childbearing potential, adequate contraception

Exclusion Criteria:

* Patients with a history of colonic resection;
* Patients with known (or newly diagnosed) inflammatory bowel disease;
* Patients with a personal history of polyposis syndrome;
* Patients with suspected chronic stricture potentially precluding complete colonoscopy;
* Patients with diverticulitis or toxic megacolon;
* Patients with a history of radiation therapy to abdomen or pelvis;
* Patients with acute lower GI bleeding
* Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.
D: Inclusion Criteria:

* all persons willing and able to undergo screening colonoscopy over the age of 55 years

Exclusion Criteria:

* any condition not compatible with the definition of screening colonoscopy

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Veritas Collagen Matrix Cystocele Repair Study - Postmarketing Protocol #CP1004
Brief Summary: The purpose of this study is to evaluate the Veritas Collagen Matrix in treating female patients with documented occurence of Pelvic Organ Prolapse as evidenced by a cystocele.


Options:
A: Inclusion Criteria:

* Stage 2 or \> anterior vaginal prolapse requiring surgical correction.
* \>18 years old
* willing to return for follow-up visits.

Exclusion Criteria:

* Less than stage II or \> anterior vaginal prolapse,
* decline to participate,
* pregnant or contemplating future pregnancy,
* anti-incontinence procedure other than midurethral sling (ie, Burch colposuspension, pubovaginal sling, or needle suspension) is planned as part of their surgical procedures,
* any contra-indication to receiving mesh or porcine dermis.
B: Inclusion Criteria:

* Patient is equal or greater than 18 years old
* Female
* Meets follow-up evaluation time frame
* Understands the nature of the procedure and has provided written informed consent
* Is scheduled to undergo vaginal pelvic reconstructive surgery
* Has \> 2nd degree midline cystocele

Exclusion Criteria:

* Presence of severe mucosal ulceration
* Previous pelvic organ prolapse surgery using an implant that will affect the use of the VCM or affect the outcome of the study
* Allergy to bovine material
* Severe mucosal atrophy
* Shortened vaginal length as determined by Investigator
* Pregnant or intends to become pregnant during study
* Has a UTI
* Has vault prolapse \< 2nd degree cystocele
C: Inclusion Criteria:

* Women aged \> 55 yr
* Women with anterior vaginal wall prolapse stage \>2 according to POP-Q classification
* Good understanding the language in word and writing

Exclusion Criteria:

* A history of previous major pelvic surgery with the exception of a hysterectomy for reasons other than genital prolapse
* Patients with previous vaginal surgery because of defects in the anterior of posterior compartments
* Previous hysterectomy because of vaginal prolapse
* Patients with prolapse of uterus or an enterocele \> stage 2
* Patients with previous TVT performed through the obturator membrane
* History of genital or abdominal cancer
* Patients treated with corticosteroids
* Not able to understand the study protocol (language problems, cognitive dysfunction etc.)
D: Inclusion Criteria:

* All patiAll patients who underwent surgery with the Avaulta synthetic mesh kit from 1/06 - 4/08.

Exclusion Criteria:

* Unable to give informed consent to participate

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Veritas Collagen Matrix Cystocele Repair Study - Postmarketing Protocol #CP1004
Brief Summary: The purpose of this study is to evaluate the Veritas Collagen Matrix in treating female patients with documented occurence of Pelvic Organ Prolapse as evidenced by a cystocele.


Options:
A: Inclusion Criteria:

* Patient is equal or greater than 18 years old
* Female
* Meets follow-up evaluation time frame
* Understands the nature of the procedure and has provided written informed consent
* Is scheduled to undergo vaginal pelvic reconstructive surgery
* Has \> 2nd degree midline cystocele

Exclusion Criteria:

* Presence of severe mucosal ulceration
* Previous pelvic organ prolapse surgery using an implant that will affect the use of the VCM or affect the outcome of the study
* Allergy to bovine material
* Severe mucosal atrophy
* Shortened vaginal length as determined by Investigator
* Pregnant or intends to become pregnant during study
* Has a UTI
* Has vault prolapse \< 2nd degree cystocele
B: Inclusion Criteria:

* Postmenopausal women with symptomatic anterior vaginal wall prolapse to the hymen or beyond when under strain and referred for reconstructive pelvic surgery

Exclusion Criteria:

* an apical defect indicating concomitant vaginal fixation, or stress urinary incontinence necessitating surgery, or her main symptomatic prolapse component was in the posterior vaginal wall.
C: Inclusion Criteria:

* Women with stage 2 or greater symptomatic rectocele
* Women electing to undergo surgical rectocele repair
* Women over age 21 years
* Women willing to comply with study procedures and follow-up

Exclusion Criteria:

* Pregnant or nursing women
* History of porcine allergy
* History of connective tissue disease, pelvic malignancy, or pelvic radiation
* Women undergoing concurrent sacral colpopexy
D: Inclusion Criteria:

* stage II or greater anterior vaginal prolapse requiring surgical correction
* age 21 years and older

Exclusion Criteria:

* less than Stage II anterior vaginal prolapse
* decline participation
* pregnant or contemplating future pregnancy
* prior anterior vaginal prolapse repair with biologic or synthetic graft
* active or latent systemic infection
* compromised immune system
* previous pelvic irradiation or cancer
* known hypersensitivity to polypropylene
* uncontrolled diabetes mellitus
* unable or unwilling to give valid informed consent
* unable or unwilling to comply with the protocol
* scheduled to undergo concomitant Burch colposuspension or pubovaginal sling

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Self-Administered High Frequency Chest Wall Oscillation Technique for Mucus Clearance in COPD: An Exploratory Pilot Project Using the SMARTVEST Device
Brief Summary: Patients with Chronic obstructive pulmonary disease (COPD) tend to have cough, excess mucus production and breathlessness as cardinal features. The excess mucus production often leads to frequent infections, exacerbations and poor quality of life. Mucociliary clearance may have an impact on improving symptoms, exercise tolerance, quality of life and reduce exacerbations.

High frequency chest wall oscillation(HFCWO) devices use percussion to the chest wall delivered from a pump through a close fitting inflatable vest. This technique has been shown to enhance mucus clearance in patients with cystic fibrosis and Bronchiectasis. This pilot study was designed to explore the feasibility, tolerance and effectiveness of the HFCWO in patients with advanced COPD.


Options:
A: Inclusion Criteria:

1. COPD; patients defined by a history of cough, breathlessness and/ mucus/sputum production with lung function showing FEV1/FVC \<70% and FEV1\<80% predicted and \< 20% reversibility from baseline on administration of nebulised b2-agonist (Salbutamol 5mg)
2. Age 40-85 years
3. Mucus hypersecretion ( \> 25 ml/72 h collection)

Exclusion Criteria:

1. Chest wall deformity (i.e., kyphoscoliosis, Rib fractures)
2. Severe osteoporosis
3. Haemoptysis within the last 3 months
4. Thoracic or abdominal surgery within 3 months
5. Respiratory failure on non-invasive ventilator therapy
6. Tracheostomy or neck deformities
7. Neuro-muscular dysfunction or disability (i.e., Paralysis due to cerebrovascular disease) which may make it impossible to use the device safely
8. Congestive heart failure (decompensated)
9. Any other mucolytic therapy
10. Significant hiatus hernia or gastro-esophageal reflux disease
11. Recent myocardial infarction or unstable angina
B: Inclusion Criteria:

1. - Non Cystic Fibrosis bronchiectasis diagnosed by High Resolution Computed Tomographic
2. - Mean sputum production ≥ 15 ml /24h
3. - Clinical stability in the last 6 weeks
4. - Not carrying out regular chest physiotherapy
5. - Forced expiratory volume in 1 second ≥ 30% pred. ; Forced Vital Capacity ≥ 45% pred. and peak expiratory flow \>270 L/s

Exclusion Criteria:

1. - Smoker or non-smoker form less than 2 years
2. - Cystic fibrosis
3. - Active tuberculosis or sarcoidosis
C: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
D: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis
Brief Summary: The aim of our study is to ascertain whether chest physiotherapy + pulmonary rehabilitation is more efficacious than chest physiotherapy alone. The outcomes that will be used to assess effectiveness are relevant in terms of the direct benefit on the patient's health related quality of life.

PLANNED STUDY: This randomized study will compare 8 weeks chest physiotherapy with 8 weeks chest physiotherapy plus pulmonary rehabilitation.


Options:
A: Inclusion Criteria:

1. - Non Cystic Fibrosis bronchiectasis diagnosed by High Resolution Computed Tomographic
2. - Mean sputum production ≥ 15 ml /24h
3. - Clinical stability in the last 6 weeks
4. - Not carrying out regular chest physiotherapy
5. - Forced expiratory volume in 1 second ≥ 30% pred. ; Forced Vital Capacity ≥ 45% pred. and peak expiratory flow \>270 L/s

Exclusion Criteria:

1. - Smoker or non-smoker form less than 2 years
2. - Cystic fibrosis
3. - Active tuberculosis or sarcoidosis
B: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
C: Inclusion Criteria:

1. COPD; patients defined by a history of cough, breathlessness and/ mucus/sputum production with lung function showing FEV1/FVC \<70% and FEV1\<80% predicted and \< 20% reversibility from baseline on administration of nebulised b2-agonist (Salbutamol 5mg)
2. Age 40-85 years
3. Mucus hypersecretion ( \> 25 ml/72 h collection)

Exclusion Criteria:

1. Chest wall deformity (i.e., kyphoscoliosis, Rib fractures)
2. Severe osteoporosis
3. Haemoptysis within the last 3 months
4. Thoracic or abdominal surgery within 3 months
5. Respiratory failure on non-invasive ventilator therapy
6. Tracheostomy or neck deformities
7. Neuro-muscular dysfunction or disability (i.e., Paralysis due to cerebrovascular disease) which may make it impossible to use the device safely
8. Congestive heart failure (decompensated)
9. Any other mucolytic therapy
10. Significant hiatus hernia or gastro-esophageal reflux disease
11. Recent myocardial infarction or unstable angina
D: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis
Brief Summary: The aim of our study is to ascertain whether chest physiotherapy + pulmonary rehabilitation is more efficacious than chest physiotherapy alone. The outcomes that will be used to assess effectiveness are relevant in terms of the direct benefit on the patient's health related quality of life.

PLANNED STUDY: This randomized study will compare 8 weeks chest physiotherapy with 8 weeks chest physiotherapy plus pulmonary rehabilitation.


Options:
A: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
B: Inclusion Criteria:

Bronchiectasis confirmed on High Resolution CT scan Clinical Bronchiectasis confirmed by a respiratory physician. Documented exacerbation within the last year. Independently mobile - i.e. able to undertake pulmonary rehabilitation

Exclusion Criteria:

* Inability to give informed consent to participate
* Age \<18 years
* Primary diagnosis of Chronic Obstructive Pulmonary Disease
* Significant comorbidity that would limit the ability to undertake pulmonary rehabilitation - i.e. Cerebrovascular, cardiovascular or musculoskeletal disease.
* Cystic Fibrosis
* Aortic aneurysm
* Recent myocardial infarction (within previous year)or unstable angina
C: Inclusion Criteria:

* aged ≥18 years diagnosis of bronchiectasis confirmed by HRCT or CT
* clinically stable (no exacerbation and no significant change in symptoms or medication in the last four weeks)
* sputum bacteriology completed over the past three months

Exclusion Criteria:

* clinically unstable (pulmonary exacerbation or any change in symptoms or medication in the last four weeks)
* current severe haemoptysis
* pregnancy or any other concomitant condition that would prevent participation
D: Inclusion Criteria:

Clinical diagnosis and/or tomographic bronchiectasis Clinically stable (no change in symptoms of dyspnea, in the amount and color of the secretion) Have completed the outpatient pulmonary rehabilitation for more than a year Not engaged in a regular physical activity.

Exclusion Criteria:

Smokers With other lung related diseases (asthma, COPD and cystic fibrosis) Severe cardiovascular diseases Musculoskeletal limitation Unable to perform the tests and the training protocol due desaturation (pulse oxygen saturation ≤ 80%) over the recommended exercise intensity.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis
Brief Summary: The aim of our study is to ascertain whether chest physiotherapy + pulmonary rehabilitation is more efficacious than chest physiotherapy alone. The outcomes that will be used to assess effectiveness are relevant in terms of the direct benefit on the patient's health related quality of life.

PLANNED STUDY: This randomized study will compare 8 weeks chest physiotherapy with 8 weeks chest physiotherapy plus pulmonary rehabilitation.


Options:
A: Inclusion Criteria:

* Acute or chronic disease requiring secretion mobilization as per hospital protocol

Exclusion Criteria:

* Absolute contraindications for positional changes
* Absolute contraindications for chest percussion
* Women visibly pregnant
* Previous enrollment in study
* Previous CPT or Vest treatment
B: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
C: Inclusion Criteria:

* Diagnosis of bronchiectasis (HRCT)
* Stable medical status for last 4 weeks
* History of 2 exacerbations in the last 2 years
* Dysnpoea on exertion (Modified Medical Research Council score \>1)

Exclusion Criteria:

* Concurrent diagnosis of COPD (physician diagnosis and history of 10 pack year smoking)
* Concurrent diagnosis of asthma (history of atopic disease and evidence of bronchodilator reversibility of 12% or 200ml in FEV1 or FVC)
* Concurrent diagnosis of Interstitial lung disease
* Concurrent diagnosis of Cystic Fibrosis
* Medical condition which could place patient at risk during exercise training (angina, neurological or orthopaedic condition)
* Prior completion of pulmonary rehabilitation within the last 12 months
D: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD

Answer: B